FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885348522> ?p ?o ?g. }

• W2885348522 endingPage "2141" @default.
• W2885348522 startingPage "2133" @default.
• W2885348522 abstract "Adequate persistence to antidiabetic treatment is highly important to achieve proper glycemic control. In this study we evaluate the persistence to treatment with dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists in a nationwide cohort of patients with type 2 diabetes. Using a central database in Hungary, we analyzed the persistence to the treatment with dipeptidyl peptidase-4 inhibitors (n = 59,900), sodium-glucose co-transporter-2 inhibitors (n = 26,052), and glucagon-like peptide-1 receptor agonists (n = 17,332) at treatment intensification between 2014 and 2016. We also compared the persistence of dipeptidyl peptidase-4 inhibitors (n = 9163) and sodium-glucose co-transporter-2 inhibitors (n = 1257) in initial therapy to that of metformin (n = 79,305) or sulfonylureas (n = 29,057). The rates of persistence to treatment and risk of non-persistence are reported. The persistence rates of dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists at treatment intensification were 69.6%, 67.8%, and 66.3% at year 1 which decreased to 57.3%, 56.8%, and 52.1% by year 2, respectively. The risk of non-persistence was higher by 6.6% (95% CI 3.6–9.6) for sodium-glucose co-transporter-2 inhibitors and by 8.3% (95% CI 5.0–11.5) for glucagon-like peptide-1 receptor agonists as compared to dipeptidyl peptidase-4 inhibitors. Novel oral antidiabetic drugs in fixed versus free add-on combinations with metformin had higher persistence. The persistence to treatment with novel oral antidiabetic drugs in initial therapy was better (dipeptidyl peptidase-4 inhibitors, 59.6% and 47.6%; sodium-glucose co-transporter-2 inhibitors, 61.9% and 47.0%) than that of initial monotherapy with metformin (47.0% and 39.1%) or sulfonylureas (52.4% and 41.8%) at years 1 and 2, respectively. Analysis of persistence of treatment with novel glucose-lowering medications revealed differences between drug classes, favoring dipeptidyl peptidase-4 inhibitors vs. sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Persistence data of novel antihyperglycemic agents may be useful for guiding the decision at initiation of antidiabetic treatment. Hungarian Diabetes Association. Plain language summary available for this article." @default.
• W2885348522 created "2018-08-22" @default.
• W2885348522 creator A5000101220 @default.
• W2885348522 creator A5028717346 @default.
• W2885348522 creator A5038399576 @default.
• W2885348522 creator A5048348589 @default.
• W2885348522 creator A5067608293 @default.
• W2885348522 creator A5089954353 @default.
• W2885348522 date "2018-08-17" @default.
• W2885348522 modified "2023-10-12" @default.
• W2885348522 title "Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study" @default.
• W2885348522 cites W1547447684 @default.
• W2885348522 cites W1837867596 @default.
• W2885348522 cites W1976182681 @default.
• W2885348522 cites W1979728198 @default.
• W2885348522 cites W1987856895 @default.
• W2885348522 cites W1993187958 @default.
• W2885348522 cites W2001475834 @default.
• W2885348522 cites W2003655151 @default.
• W2885348522 cites W2009830637 @default.
• W2885348522 cites W2026991703 @default.
• W2885348522 cites W2027073279 @default.
• W2885348522 cites W2056824040 @default.
• W2885348522 cites W2136950115 @default.
• W2885348522 cites W2139062201 @default.
• W2885348522 cites W2141001773 @default.
• W2885348522 cites W2163153907 @default.
• W2885348522 cites W2168261002 @default.
• W2885348522 cites W2586129535 @default.
• W2885348522 cites W2605480172 @default.
• W2885348522 cites W2748858803 @default.
• W2885348522 cites W2753501156 @default.
• W2885348522 cites W2761594440 @default.
• W2885348522 cites W2767408736 @default.
• W2885348522 cites W2770940237 @default.
• W2885348522 cites W2781836119 @default.
• W2885348522 cites W2791469895 @default.
• W2885348522 cites W2804732925 @default.
• W2885348522 cites W2995951612 @default.
• W2885348522 doi "https://doi.org/10.1007/s13300-018-0483-4" @default.
• W2885348522 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6167279" @default.
• W2885348522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30120754" @default.
• W2885348522 hasPublicationYear "2018" @default.
• W2885348522 type Work @default.
• W2885348522 sameAs 2885348522 @default.
• W2885348522 citedByCount "19" @default.
• W2885348522 countsByYear W28853485222019 @default.
• W2885348522 countsByYear W28853485222020 @default.
• W2885348522 countsByYear W28853485222021 @default.
• W2885348522 countsByYear W28853485222022 @default.
• W2885348522 countsByYear W28853485222023 @default.
• W2885348522 crossrefType "journal-article" @default.
• W2885348522 hasAuthorship W2885348522A5000101220 @default.
• W2885348522 hasAuthorship W2885348522A5028717346 @default.
• W2885348522 hasAuthorship W2885348522A5038399576 @default.
• W2885348522 hasAuthorship W2885348522A5048348589 @default.
• W2885348522 hasAuthorship W2885348522A5067608293 @default.
• W2885348522 hasAuthorship W2885348522A5089954353 @default.
• W2885348522 hasBestOaLocation W28853485221 @default.
• W2885348522 hasConcept C126322002 @default.
• W2885348522 hasConcept C127413603 @default.
• W2885348522 hasConcept C134018914 @default.
• W2885348522 hasConcept C156490143 @default.
• W2885348522 hasConcept C170493617 @default.
• W2885348522 hasConcept C185280430 @default.
• W2885348522 hasConcept C187320778 @default.
• W2885348522 hasConcept C2776398474 @default.
• W2885348522 hasConcept C2777180221 @default.
• W2885348522 hasConcept C2778563252 @default.
• W2885348522 hasConcept C2778763485 @default.
• W2885348522 hasConcept C2778938600 @default.
• W2885348522 hasConcept C2779306644 @default.
• W2885348522 hasConcept C2780323712 @default.
• W2885348522 hasConcept C2781009140 @default.
• W2885348522 hasConcept C555293320 @default.
• W2885348522 hasConcept C71924100 @default.
• W2885348522 hasConcept C98274493 @default.
• W2885348522 hasConceptScore W2885348522C126322002 @default.
• W2885348522 hasConceptScore W2885348522C127413603 @default.
• W2885348522 hasConceptScore W2885348522C134018914 @default.
• W2885348522 hasConceptScore W2885348522C156490143 @default.
• W2885348522 hasConceptScore W2885348522C170493617 @default.
• W2885348522 hasConceptScore W2885348522C185280430 @default.
• W2885348522 hasConceptScore W2885348522C187320778 @default.
• W2885348522 hasConceptScore W2885348522C2776398474 @default.
• W2885348522 hasConceptScore W2885348522C2777180221 @default.
• W2885348522 hasConceptScore W2885348522C2778563252 @default.
• W2885348522 hasConceptScore W2885348522C2778763485 @default.
• W2885348522 hasConceptScore W2885348522C2778938600 @default.
• W2885348522 hasConceptScore W2885348522C2779306644 @default.
• W2885348522 hasConceptScore W2885348522C2780323712 @default.
• W2885348522 hasConceptScore W2885348522C2781009140 @default.
• W2885348522 hasConceptScore W2885348522C555293320 @default.
• W2885348522 hasConceptScore W2885348522C71924100 @default.
• W2885348522 hasConceptScore W2885348522C98274493 @default.
• W2885348522 hasIssue "5" @default.
• W2885348522 hasLocation W28853485221 @default.
• W2885348522 hasLocation W28853485222 @default.

• next